South Asian Journal of Cancer

LUNG CANCER: ORIGINAL ARTICLE
Year
: 2017  |  Volume : 6  |  Issue : 1  |  Page : 1--5

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy


Senthil Rajappa1, Dinesh Chandra Doval2, Jaydip Biswas3, Shekar Patil4, Naresh Somani5, Sankar Srinivasan6, Shailesh Bondarde7, Nitin S Palwe8, Binay Swarup8 
1 Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India
2 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India
3 Department of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India
4 Department of Medical Oncology, HCG Bangalore Institute of Oncology, Bengaluru, Karnataka, India
5 Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India
6 Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu, India
7 Department of Medical Oncology, Shatabdi Super Speciality Hospital, Suyojit City Centre, Nashik, Maharashtra, India
8 Department of Medical, Roche Products (India) Pvt. Ltd, Mumbai, Maharashtra, India

Correspondence Address:
Binay Swarup
Department of Medical, Roche Products (India) Pvt. Ltd, Mumbai, Maharashtra
India

Background: First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC) patients without progression after four cycles of chemotherapy was well tolerated and significantly prolonged progression-free survival (PFS) compared with placebo. Aim and Design: This open-label, single arm, Phase IV, interventional study was designed to evaluate erlotinib as first-line maintenance after chemotherapy in Indian NSCLC patients. Primary efficacy objective was to evaluate PFS rate (PFSR) at week 52 and secondary objectives were determination of PFS, overall survival (OS), overall response rate (ORR), disease control rate, and safety. Subjects and Methods: Patients were treated with erlotinib until disease progression/death/unacceptable toxicity or end of study. Patients with disease progression underwent scheduled clinical assessments every 12 weeks thereafter. Kaplan–Meier estimates were used to evaluate PFSR, PFS, and OS. The ORR was summarized using number and percentage along with two-sided 95% Clopper–Pearson confidence interval. The incidence of adverse events (AEs) and serious AEs (SAEs) was tabulated according to severity, outcome, and relationship to erlotinib. Results: Of the 51 enrolled patients, 47 patients completed the study (2: Continuing treatment, 41: Disease progression, and 4: Death) and four patients discontinued treatment (3: Lost to follow-up; 1: Withdrew consent). PFSR was 22.5% at 12 months, median PFS 99 days (14.14 weeks), and median OS was 671 days (22 months). The probability of OS was 74.5% at 14 months. The ORR was 25.5%, and disease control rate was 55.3%. AEs were reported in 62.7% and SAE in 7.8% of patients. Common AEs were diarrhea and rash. Conclusions: Erlotinib was well tolerated by Indian patients in first-line maintenance setting and resulted in median PFS of 14 weeks and median OS of 22 months better than previously reported and with no new safety concerns in this population.


How to cite this article:
Rajappa S, Doval DC, Biswas J, Patil S, Somani N, Srinivasan S, Bondarde S, Palwe NS, Swarup B. Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy.South Asian J Cancer 2017;6:1-5


How to cite this URL:
Rajappa S, Doval DC, Biswas J, Patil S, Somani N, Srinivasan S, Bondarde S, Palwe NS, Swarup B. Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy. South Asian J Cancer [serial online] 2017 [cited 2017 Nov 25 ];6:1-5
Available from: http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=1;spage=1;epage=5;aulast=Rajappa;type=0